28th Jan 2009 07:00
Immunodiagnostic Systems Holdings plc
IDS iSYS Launch Status
Immunodiagnostic Systems Holdings plc ("IDS" or "the Company"), a leading producer of diagnostic testing kits for the clinical and research markets, continues to make steady progress towards the launch of its fully-automated immunoanalyser, the IDS iSYS.
The IDS iSYS will launch with the company's flagship product, a test to quantify vitamin D in patient serum or plasma, in February. Demand for vitamin D testing has been growing strongly in recent times due to the increasing awareness of the importance of 'adequacy' in vitamin D in reducing predisposition to numerous disease conditions, including common cancers (colon, breast and prostate) and autoimmune disease, as well as the long accepted role in building strong bones and teeth.
The Chief Executive Officer, Dr Roger Duggan, stated
"We are on track for a February launch. The assay has now successfully transferred from development to production, and final validation is advanced both internally and at a number of external beta sites. The performance of the system is exceeding specifications and we have more than 30 customers wanting to try the assay in their own laboratories immediately on launch. Based on comparative data generated, I am very confident that the new IDS iSYS Vitamin D assay will bring the quality and analytical excellence for which we are known in the manual vitamin D market to the automated testing market, and address the shortcomings of our competitors' existing automated methods".
Enquiries:
|
IDS |
Oriel Securities Ltd |
Parkgreen Communications Ltd |
|
Nominated Advisor and broker |
||
|
Roger Duggan, CEO |
Andrew Edwards |
Paul McManus |
|
Paul Hailes, Finance Director |
||
|
Tel: 0191 519 0660 |
Tel: 020 7710 7600 |
Tel: 020 7933 8787 |
|
Mob: 07980 541 893 |
||
|
www.idsplc.com |
Related Shares:
IDH.L